Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia

References

• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia 2000;14:480–487.
   PubMed Web of Science ®Google Scholar
• Estey EH. How I treat older patients with AML. Blood 2000;96: 1670–1673.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006;108:3280–3288.
   PubMed Web of Science ®Google Scholar
• Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006;108:63–73.
   PubMed Web of Science ®Google Scholar
• Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000;71:238–244.
   PubMed Web of Science ®Google Scholar
• Wu L, Li X, Su J, et al. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS. J Cancer Res Clin Oncol 2011; 137:1563–1569.
   PubMed Web of Science ®Google Scholar
• Qian SX, Li JY, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007:31:1383–1388.
   PubMed Web of Science ®Google Scholar
• Huang MT. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 1975:11:511–519.
   PubMedGoogle Scholar
• Fresno M, Jiménez A, Vázquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977;72: 323–330.
   PubMedGoogle Scholar
• Xie WZ, Lin MF, Huang H, Cai Z. Homoharringtonine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of telomerase. Am J Chin Med 2006;34:233–244.
   PubMed Web of Science ®Google Scholar
• Cai Z, Bao HY, Lin MF. Correlation between survivin mRNA expression and homoharringtonine induced apoptosis of malignant hematopoietic cells. Chin Med J (Engl) 2005;118:548–554.
   PubMed Web of Science ®Google Scholar
• Jin J, Jiang DZ, Mai WY, et al. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia. Leukemia 2006;20:1361–1367.
   PubMed Web of Science ®Google Scholar
• Te Boekhorst PA, Löwenberg B, Vlastuin M, et al. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993;7:1191–1198.
   PubMed Web of Science ®Google Scholar
• Bai A, Kojima H, Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 1999;27:259–265.
   PubMed Web of Science ®Google Scholar
• Rombouts EJ, Pavic B, Lowenberg B, et al. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004;104:550–557.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Kohara H, Noda M, et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006;25: 977–988.
   PubMed Web of Science ®Google Scholar
• De La Luz Sierra M, Gasperini P, McCormick PJ, et al. Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells. Blood.2007;110:2276–2285.
   PubMed Web of Science ®Google Scholar
• Semerad CL, Christopher MJ, Liu F, et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005;106:3020–3027.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006;106:1090–1098.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004;103:479–485.
   PubMed Web of Science ®Google Scholar
• van der Holt B, Löwenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005;106:2646–2654.
   PubMed Web of Science ®Google Scholar
• Suzushima H, Wada N, Yamasaki H, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia. Leuk Res 2010;34:610–614.
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008;112:1638–1645.
   PubMed Web of Science ®Google Scholar
• Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002;100:3869–3876.
   PubMed Web of Science ®Google Scholar
• Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007;138:186–195.
   PubMed Web of Science ®Google Scholar
• Fernandez-Mercado M, Yip BH, Pellagatti A, et al. Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics. PLoS One 2012;7:e42334.
   PubMed Web of Science ®Google Scholar
• Shen Y, Zhu YM, Fan X, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 2011;118:5593–5603.
   PubMed Web of Science ®Google Scholar
• Legha SS, Keating M, Picket S, et al. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 1984;68:1085–1091.
   PubMedGoogle Scholar
• Warrell RP Jr, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 1985;3:617–621.
   PubMed Web of Science ®Google Scholar
• Gu LF, Zhang WG, Wang FX, et al. Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2011;137:997–1003.
   PubMed Web of Science ®Google Scholar